AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio.
AstraZeneca has started the week off strong by announcing their intentions to construct an ADC manufacturing facility in Singapore, which will be supported by the Singapore Economic Development Board (EDB). The greenfield facility will be the drugmaker’s first end-to-end ADC production site with fully integrated manufacturing processes at the commercial scale. ADC manufacturing requires a multi-step process, including antibody production, synthesis of chemotherapy drugs and linkers, the conjugation of the drug-linker to antibodies, and filling of completed ADC substance. The facility is intended to streamline the ADC manufacturing process for AstraZeneca.
Chairman of the EDB Png Cheong Boon comments, “We welcome AstraZeneca’s decision to establish a manufacturing presence in Singapore for the first time. It will also be a first for AstraZeneca – an end-to-end manufacturing facility for novel antibody–drug conjugates that enables precision therapy for cancer. This greenfield investment is a strong show of confidence in Singapore’s biopharmaceutical manufacturing capabilities and talent, strengthens our ecosystem in supporting the development and manufacturing of precision medicines, and creates meaningful jobs and economic opportunities for Singapore. We look forward to a successful partnership with AstraZeneca.”
AstraZeneca currently maintains a portfolio of in-house ADCs, with six wholly owned clinical ADCs and more in preclinical development. The pharmaceutical giant will also work with the Singaporean government to offer green solutions at the ADC facility. It will be designed to emit zero carbon from the first day of operations. Design and construction of the facility is set to start at the end of the year, with manufacturing operations to begin in 2029.
Pascal Soriot, AstraZeneca’s CEO, states, “AstraZeneca has built an industry-leading portfolio of cancer medicines, including antibody–drug conjugates, which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country.”
Source:
AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore [Accessed May 21, 2024] https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html
Related News
-
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb... -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin... -
News Women in Pharma: Diversi‘tea’ at CPHI North America
CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati... -
News CPHI Online Webinar Series – Optimising Pharma Manufacturing through Digital Transformations
This month’s CPHI Webinar Series explored achieving manufacturing excellence in pharma through the digitalisation of daily processes. Presented by Joe Doyle, Head of Sales at EviView, and Bikash Chatterjee, President and Chief Scientific Off...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance